Wipfli Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Wipfli Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$555K	Buy	+805	New	+$507K	0.04%	207

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wipfli Financial Advisors's REGN Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2022: 805 shares worth $555K. The stake represents 0.04% of the portfolio and ranks #207 among its holdings.

1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Wipfli Financial Advisors held 805 shares of Regeneron Pharmaceuticals worth $555K as of Q3 2022.
Regeneron Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Regeneron Pharmaceuticals made up 0.04% of Wipfli Financial Advisors's portfolio in Q3 2022, its #207 holding.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.